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ABSTRACT 
Background: Dietary nitrate supplementation has been shown to reduce the oxygen (O2) cost of 
exercise and enhance exercise tolerance in healthy individuals. This study assessed whether 
similar effects could be observed in individuals with type 2 diabetes (T2DM). 
Methods: In a randomised, double blind, placebo-controlled cross-over study, 48 participants 
with T2DM supplemented their diet for four days with either nitrate rich beetroot juice (70 
ml/day, 6.43 mmol nitrate/day) or nitrate depleted beetroot juice as placebo (70 ml/day, 0.07 
mmol nitrate/day).  After each intervention period, resting plasma nitrate and nitrite 
concentrations were measured subsequent to participants completing moderate-paced walking. 
Pulmonary gas exchange was measured to assess the O2 cost of walking.  Following a rest 
period, participants performed the six-minute walk test (6MWT). 
Results: Relative to placebo, beetroot juice resulted in a significant increase in plasma nitrate 
(placebo: 57 ± 66 vs. beetroot: 319 ± 110 µM; P <0.001) and plasma nitrite concentration 
(placebo: 680 ± 256 vs. beetroot: 1065 ± 607 nM; P <0.001). There were no differences between 
placebo juice vs. beetroot juice for the O2 cost of walking (946 ± 221 vs. 939 ± 223 ml
.min-1, 
respectively; P =0.59), and distance covered in the 6MWT (550 ± 83 vs. 554 ± 90m, 
respectively; P =0.17). 
Conclusion: Nitrate supplementation did not affect the O2 cost of moderate-paced walking or 
improve performance in the 6MWT. These findings indicate that dietary nitrate supplementation 
does not modulate the response to exercise in individuals with T2DM.  
Trail Registration: ClinicalTrials.gov NCT02206074 
Funding: Diabetes UK  
Keywords: Type 2 diabetes; Nitrate; Nitric oxide; Exercise; Blood pressure  
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Abbreviations: 
ACEi – Ace inhibitor 
ARB – Angiotensin receptor blocker 
Asymmetric dimethylarginine - ADMA 
Carbon dioxide – CO2 
Heart rate – HR 
MRT – Mean response time 
Nitric oxide – NO 
Nitric oxide synthase – NOS 
Oxygen – O2 
Oxygen uptake - V̇O2 
Reactive oxygen species - ROS 
Six-minute walk test – 6MWT  
Type 2 diabetes – T2DM 
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INTRODUCTION 
Individuals with type 2 diabetes mellitus (T2DM) have profound reductions in their 
tolerance to exercise compared to healthy individuals 1. The discomfort experienced by 
individuals with T2DM during exercise may impact upon their ability or willingness to attain 
their recommended level of exercise, which is a key aspect of disease management 2. Exercise 
intolerance in this population has been attributed to abnormalities at multiple points during the 
transport of oxygen (O2) from the lungs to its site of utilisation in the muscles
3-5. There is 
evidence that individuals with T2DM have reductions in the biosynthesis and bioavailability of 
the biological messenger nitric oxide (NO) 6,7.  NO is known to play an important role in muscle 
contractility, skeletal muscle glucose uptake, calcium handling 8, vascular function, blood flow 
regulation 9, and mitochondrial respiration and biogenesis 10.  
There are two known pathways by which NO is synthesised, the L-arginine pathway and 
the entero-salivary pathway. The L-arginine pathway involves the synthesis of NO from L-
arginine by the nitric oxide synthase (NOS) family of enzymes. The entero-salivary pathway 
involves a stepwise conversion of nitrate to nitrite, and subsequently, nitrite to NO. Briefly, 
nitrate from the diet (or from NO/nitrite oxidation) is absorbed into the circulation where it is 
concentrated in the salivary glands. Nitrate is then reduced to nitrite via facultative anaerobic 
bacteria on the surface of the tongue 11 and subsequently swallowed. Some of the swallowed 
nitrite is reduced to NO in the acidic environment of the stomach, with important local effects on 
gastric function and protection against enteric pathogens 12, and the remainder enters the 
circulation. Circulating nitrite acts as a reservoir for NO, with its reduction to NO potentiated in 
acidic or hypoxic areas, such as contracting skeletal muscle 13. It has been suggested that the 
entero-salivary pathway is a complementary system for NO synthesis 14. 
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There is extensive evidence in healthy individuals that nitrate supplementation, via either 
sodium nitrate or nitrate rich beetroot juice, increases plasma nitrite concentration 15,16, lowers 
blood pressure (BP) 17,18, and reduces the O2 cost of exercise 
15,19,20.  The reduction in the O2 cost 
of exercise has been proposed to be related to a reduction in the ATP cost of muscle force 
production 17, an improvement in mitochondrial efficiency 21, or a combination of both 22. 
It has been reported that the bioavailability of NO is reduced in individuals with T2DM 
due to increased scavenging and/or reduced synthesis. Reactive oxygen species (ROS) 23 and 
hyperglycaemia 24 may result in lower L-arginine derived NO. Further, there is evidence that NO 
production is suppressed by NOS inhibitors such as asymmetric dimethylarginine (ADMA) 25 
and caveolin-1 26, which are elevated in T2DM. Conversely, others have reported increased 
plasma nitrate and nitrite concentrations in individuals with T2DM 27,28, which may indicate a 
quenching of NO activity or upregulation of NO synthesis to counteract resistance. It is possible 
that dietary nitrate supplementation in this population could ameliorate the impact of T2DM on 
NOS dependent NO synthesis by increasing the amount of NO produced via the entero-salivary 
pathway 14.  We recently reported no effect of dietary nitrate supplementation on the 24h 
ambulatory BP in individuals with T2DM 12, but the impact on the O2 cost of exercise, and 
exercise tolerance in individuals with T2DM remains unknown.  
The aim of this study was, therefore, to examine the effects of dietary nitrate 
supplementation (nitrate rich beetroot juice) on the O2 cost of exercise and walking performance, 
and to confirm our previous finding regarding resting BP, in individuals with T2DM. It was 
hypothesised that, compared to nitrate depleted beetroot juice, nitrate rich beetroot juice would 
reduce the amount of O2 required per unit of time to perform moderate-paced walking, and 
increase the distance covered in the 6-minute walk test. 
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METHODS 
Patients 
Forty eight patients (35 males) with T2DM (see Table 1 for characteristics) volunteered 
to participate in this randomised, double blind, placebo-controlled cross-over study. Participants 
were recruited from the NIHR Exeter Clinical Research Facility, Exeter 10,000 cohort, a 
database of individuals who have consented to be contacted for research. Ethical approval was 
granted by the Cornwall and Plymouth NRES Committee 12/SW/0118 and the study was 
registered as a clinical trial on the ClinicalTrials.gov website, ID # NCT02206074. All 
participants provided written informed consent. Patients were recruited if they had been 
diagnosed with T2DM (as defined by the WHO) at least five years prior to enrolment in the 
study and were 35−75 years of age. Patients were excluded from the study if they had significant 
renal impairment (eGFR <30), uncontrolled hypertension, a BMI <25 or >35 (kg/m2), a history 
of myocardial infarction or cerebro-vascular event, were taking regular organic nitrates or 
nicorandil, or were smokers (or who had stopped smoking within the previous three months). 
Patients taking phosphodiesterase inhibitors were asked to refrain from doing so for the duration 
of the study. On experimental days, participants were asked to arrive at the laboratory in a rested 
and fully hydrated state, at least 3 hours postprandial, and having avoided caffeine and alcohol 
for 6 and 24 hours, respectively. Participants were also asked to avoid exercise for 24 hours prior 
to each testing session.  Participants were asked to record their diet for 24 hours prior to each 
experimental visit. Following the crossover the participant was asked to replicate their previous 
diet and this was verbally confirmed at the second visit. 
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Table 1. Characteristics of patients included in the final analysis. Data are mean ± SD, or as a % 
of the cohort on a medication.   
 
    
 
Age (years)   63.35 ± 7.27 
 
 
Diabetes Duration (years)  
 
10.31 ± 5.26 
 
 
HbA1c (mmol/mol) 
 
60.83 ± 13.37 
 
 
Body Mass Index (kg/m2)  
 
30.17 ± 2.93 
 
 
Baseline systolic BP (mmHg)  
 
142.13 ± 12.84 
 
 
Baseline diastolic BP (mmHg)  
 
80.85 ± 7.36 
 
 
No. of 30+ minutes of exercise per week  
 
3.83 ± 3.16 
 
 
Portions of fruit and vegetables per day 
 
3.83 ± 2.00 
 
 
Metformin % 
 
83.33 
 
 
Insulin % 
 
25.00 
 
 
ARB & ACEi % 
 
47.92 
  Statins %   83.33 
 
      
Pre-experimental tests 
Participants attended the NIHR Exeter Clinical Research Facility where we completed 
informed consent, a medical history, anthropometric measures, and a resting ECG. A 
familiarisation session was performed for the treadmill exercise, allowing the determination of 
the walking speed for each participant that would be used in the experimental visits. The target 
speed was a pace equivalent to the participants’ usual walking speed that could comfortably be 
maintained for 6 minutes. 
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Experimental Overview 
Following the pre-experimental visit, participants were assigned in a double-blind, 
randomised, crossover design to consume 70 ml/day of nitrate rich beetroot juice (beetroot juice; 
containing 6.43 mmol of nitrate; Beet it, James White Drinks Ltd., Ipswich) or nitrate depleted 
beetroot juice (placebo; nitrate depleted beetroot juice containing 0.07 mmol of nitrate; Beet it, 
James White Drinks Ltd., Ipswich) for four days. The dose of 6.43 mmol of nitrate equated to 
0.072 mmol.kg-1 per day for 3.5 days. Similar dosing regimens (0.068 17; 0.064 29;  0.086 
30mmol.kg-1) to ours have been shown to be effective at this relative dose. Production of the 
placebo juice has been detailed previously 31, with the final product being indistinguishable in 
taste, colour, texture, appearance and odour to the nitrate rich beetroot juice 32. The final 70 ml of 
juice was consumed ~3 hours before the commencement of exercise on the morning of testing. 
Participants were required to abstain from using antibacterial mouthwash and chewing gum 
throughout the study, as this has been shown to reduce the concentration of oral bacteria 
responsible for the reduction of nitrate to nitrite 33.   
During the two experimental visits, resting BP was measured and venous blood samples 
were drawn into lithium-heparin tubes (Sarstedt S-Monovette, Nümbrecht, Germany) and 
prepared for nitrate and nitrite analysis as previously described 34. Subsequently, participants 
performed 3 bouts of walking on a motorised treadmill (NordicTrack T14.0, Chaska, MN, USA) 
at the target speed that was determined in the pre-experimental visit. Each bout was preceded by 
a resting baseline period of three minutes, with the three bouts separated by 15 minutes of 
passive recovery. Following a further 15 minutes of seated rest, participants performed a 6 
minute walk test (6MWT) to assess functional capacity. This test was conducted indoors on a 
straight, flat course between 2 cones which were 32.2 meters apart, with patients instructed to 
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cover as much distance as possible in the allotted time. Standardised verbal encouragement was 
given throughout.  Following their first experimental visit, participants began a washout period 
(10-14 days) before entering the opposing arm of the study. 
Measurements  
Prior to any exercise testing during the experimental visits, resting BP of the brachial 
artery was measured using an automated sphygmomanometer (Omron M6, Kyoto, Japan). Five 
measurements were taken in total, with the mean of the final three measurements being recorded. 
For the determination of plasma nitrite concentration, venous blood samples (~4 ml) were 
drawn into lithium-heparin tubes (Sarstedt S-Monovette, Nümbrecht, Germany), centrifuged, 
aliquoted and immediately frozen in liquid nitrogen and stored at -80ºC. Prior to analysis all 
samples were deproteinized using a variant of the protocol used by Higuchi, Motomizu 35. Fresh 
reagents were created each day and checked for contamination. No contamination was detectable 
for water, sodium hydroxide, zinc sulphate or sodium iodide. Determination of plasma nitrate 
and nitrite concentrations was performed on a nitric oxide analyser via ozone chemiluminescence 
(Sievers NOA 280; Analytix Ltd, Durham, UK) using the protocol described by Bateman, Ellis, 
Freeman 36. 
  Pulmonary gas exchange was measured breath by breath during all treadmill 
walking exercise (MedGraphics CardiO2 Cardiopulmonary Diagnostic Systems, St. Paul, MN, 
USA). The volume transducer was calibrated before each test with a 3-liter calibration syringe 
(Hans Rudolph, Kansas City, MO, USA) and the O2 and CO2 analysers were calibrated using 
gases of known concentration.  During treadmill walking exercise, heart rate (HR) was measured 
every 5 seconds via telemetry (Polar R5400sd, Kempele, Finland).  
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Data Analysis  
The breath by breath oxygen uptake (V̇O2) data were initially inspected for errant breaths 
(e.g. associated with coughing and swallowing), with values lying more than four SDs from the 
local mean being removed. The breath-by-breath data were linearly interpolated to provide 
second-by-second values and, for each individual, the three bouts were time-aligned to the start 
of exercise and ensemble-averaged. A nonlinear least-square algorithm was used to fit the data, 
as described in the following equation: 
 V̇O2 (t) = V̇O2 baseline + Ap(1-e-(t-TDp)/
τp) 
where V̇O2 (t) represents the absolute V̇O2 at a given time t; V̇O2baseline represents the mean V̇O2 in 
the baseline period (when participants were stood still on the treadmill); Ap, TDp, and p 
represent the amplitude, time delay, and time constant, respectively, describing the increase in 
V̇O2 above baseline when exercise had commenced. The end-exercise V̇O2 was defined as the 
mean V̇O2 measured over the final 30 seconds of exercise. The mean response time (MRT) was 
calculated by fitting a single exponential curve to the data with no time delay from the onset to 
the end of exercise. The O2 deficit was calculated as the product of the V̇O2 response amplitude 
(i.e. the baseline to the point that a steady state was attained) and the MRT.  For a schematic 
representation of the V̇O2 kinetics parameters, see Figure 1. 
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Figure 1. Schematic showing the parameters of the oxygen uptake kinetics on a representative 
participant’s data. 
 
Juice analysis  
It has previously been suggested that the antioxidant content of beetroot juice may have 
beneficial effects 37. In order to establish whether the concentrations of known antioxidants in 
beetroot juice (polyphenols and betacyanins) were different in the active and placebo juice, both 
were analysed using the high-performance liquid chromatography technique according to our 
previously described methods 38. 
Sample size and randomisation 
An a priori sample size calculation was performed by a statistician from the University of 
Exeter Medical School. A pilot study (n=6) in individuals who have T2DM revealed a mean 
difference between beetroot juice and placebo juice of 45 ml.min-1 for end exercise V̇O2 (1SD) 
during cycling exercise. For 90% power and an α-level set at P = 0.05 (two tailed), to detect a 0.5 
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SD difference 44 patients were required. In order to account for dropout, we anticipated that 48 
patients would begin the study. Each participant was randomised by a research nurse, who also 
supplied them with the appropriate juice.   
Data and statistical analysis 
All data were tested for normality and are presented as means ± standard deviation (SD) 
unless otherwise stated.  Differences in plasma nitrate and nitrite concentrations, BP, V̇O2, and 
distance covered in the 6-minute walk test between the conditions were analysed using two-
tailed, paired-samples t-tests. Where normality of data was not met, differences between the 
aforementioned data were tested using a non-parametric test (Wilcoxon rank-sum test). When the 
sample was split for patients taking different classes of medications, independent samples t-tests 
were performed. Pearson product–moment correlation coefficients were used to assess the 
relationships between variables. Statistical analyses were performed on SPSS software version 
21.0 (Chicago, IL, USA), with statistical difference accepted when P < 0.05.   
 
Results 
48 subjects completed the study.  For detailed information regarding participant 
recruitment and withdrawal, see Figure 2.  Participants’ self-reported adherence to beetroot juice 
and avoidance of mouth wash was 100% for both arms of the study. All participants reported 
similar physical activity and dietary patterns for both supplementation periods. The ingestion of 
both juices was well tolerated with no adverse side effects. As in previous studies using beetroot 
juice supplementation, participants reported beeturia (red urine) and red stools 15.  
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Figure 2. Flow diagram of trial 
 
Plasma nitrate and nitrite concentrations: Relative to placebo, beetroot juice resulted in a 
significant increase in plasma nitrate concentration (placebo: 57 ± 66 vs. beetroot juice 319 ± 
90µM, P < 0.001, 95% CI -220, 302; Figure 3A). Plasma nitrite concentration also increased for 
beetroot juice in comparison to placebo (placebo: 680 ± 256 vs. beetroot juice 1065 ± 607 nM, P 
< 0.001, 95% CI -220, 548; Figure 3B). There were no differences in baseline (placebo) plasma 
nitrite when subjects were split into groups based on drug classes; ACEi and ARB (n= 25; 
difference vs. those not on these drugs -68 ± 75 nM, P = 0.37, 95% CI -218, 83), metformin (n = 
40; difference -18 ± 105 nM, P = 0.87, 95% CI -231, 196), insulin (n= 12; difference 3 ± 86 nM, 
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P = 0.97, 95% CI -171, 177) statins (n = 40; difference 164 ± 97 nM, P = 0.09, 95% CI -31, 360) 
and sulphonylurea (n = 15; difference 35 ± 134 nM, P = 0.79, 95% CI -237, 306). Other 
classifications of drugs were prescribed, however the sample size was too small to make 
inferences; gliptins (n = 2), exenatide (n = 2), sulfazalazine (n = 1), alpha blocker (n = 3), beta 
blocker (n = 1), calcium channel blocker (n = 6), loop diuretic (n = 1), thiazide (n = 2) P > 0.05).  
 
Figure 3. A depicts plasma nitrate and B shows plasma nitrite group mean concentrations 
analysed via chemiluminescence. Values are means ± SD. *significantly different from the 
placebo P < 0.001. 
 
Treadmill walking, V̇O2 kinetics, and heart rate: Relative to placebo, beetroot juice 
supplementation had no effect on baseline (placebo: 282 ± 50 vs. beetroot juice: 281 ± 46 
ml.min-1; P = 0.82, 95% CI -12.9, 10.21) or end-exercise V̇O2 (placebo: 939 ± 223 vs. beetroot 
A 
B 
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juice: 946 ± 221 ml.min-1; P = 0.60, 95% CI -20, 34.3; Figure 4). The time constant and MRT of 
V̇O2 response, and the O2 deficit were also not different between conditions (see Table 2). End-
exercise heart rate was not different between conditions (placebo: 96 ± 12 vs. beetroot juice: 94 
± 11 BPM, P = 0.36, 95% CI -4.7, 1. 7). No significant correlation was observed between the 
change in plasma nitrite concentration and end-exercise V̇O2 (r = 0.04, P = 0.77). 
 
Figure 4. The group mean pulmonary oxygen uptake response for placebo (A) and nitrate-rich 
beetroot (B). The vertical line represents the initiation of walking exercise from the standing 
baseline. Group mean responses are shown with error bars every 30s.  
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Table 2. Oxygen uptake kinetics during walking exercise with placebo and nitrate-rich beetroot  
supplementation. Data are mean ± SD. 
 
 
Six minute walk test: No difference was found between placebo and beetroot juice for 
distance covered during the six minute walk test (placebo: 554 ± 90 vs. beetroot juice: 550 ± 83 
m, P = 0.17, 95% CI -11, 2.04). No difference was observed for distance covered during the six 
minute walk test when the group was split for ACEi and ARB compared with individuals not on 
this classification of drug (change -7.6 ± 44.6 m, P = 0.25, 95% CI -20.6, 5.4).  
Blood pressure: Comparisons between placebo and beetroot juice revealed no statistically 
significant effect on systolic BP (placebo: 134 ± 10 vs. beetroot juice: 132 ± 12 mmHg, P = 0.17, 
95% CI -4.09, 1.17) or diastolic BP (placebo: 77 ± 7 vs. beetroot juice: 76 ± 11 mmHg, P = 0.27, 
95% CI -4.04, 0.74; Figure 5 A and B).  
   
                                                                    Placebo              Beetroot juice      
Baseline (ml.min-1) 282 ± 50 281 ± 46 
Primary amplitude (ml.min-1)  656 ± 205 665 ± 199 
End-exercise (ml.min-1) 938 ± 223 946 ± 221 
O2 deficit (L
.min-1) 0.48 ± 0.17 0.50 ± 0.19 
Mean response time (s) 45 ± 10 45 ± 10 
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Figure 5. Effects of nitrate on blood pressure, A: Groups means for systolic blood pressure and B 
depicts the group mean for diastolic blood pressure. Values are means ± SD.  
 
Antioxidants in beetroot juice: Antioxidant concentrations in placebo and active beetroot 
juice are displayed in Table 3. 
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Table. 3. The content of total betacyanins and polyphenol compounds in two different beetroot 
juices. Table A, depicts all identified compounds and figure B shows the compound groups. 
Mean value ± standard deviation (in mg/100 ml of fresh juice). 
 
 
Identified compound Beetroot juice Placebo 
Betanin-3-O-glucoside 452.71 ± 19.56  519.31 ± 11.43  
Betanidine 6.03 ± 0.40  3.61 ± 0.19  
Gallic acid 1.80 ± 0.12  1.43 ± 0.14  
Chlorogenic acid 3.03 ± 0.55  2.10 ± 0.22  
Caffeic acid 0.90 ± 0.20  0.58 ± 0.11  
Ferulic acid 0.56 ± 0.00  0.53 ± 0.01  
Rutinoside-3-O-quercetin 1.97 ± 0.08  1.81 ± 0.04  
Glucoside-3-O-quercetin 0.89 ± 0.04  0.83 ± 0.02  
Myrycetin 0.44 ± 0.01  0.47 ± 0.02  
Luteolin 0.23 ± 0.01  0.16 ± 0.01  
Quercetin 0.25 ± 0.01  0.19 ± 0.00  
Kaempferol 0.22 ± 0.01  0.17 ± 0.00  
 
 
 
Group of compounds Beetroot juice Placebo 
Total betacyanins         458.73 ±1 9.73         522.92 ± 11.43  
Total polyphenols 10.29 ± 0.72  8.30 ± 0.34  
Total phenolic acids 6.30 ± 0.67  4.65 ± 0.34  
Total flavonoids 3.99 ± 0.10  3.65 ± 0.05  
   
   
 
 
A 
B 
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Discussion  
This is the first study to investigate the effects of dietary nitrate supplementation on the 
exercise responses of individuals with T2DM. The principal findings of this investigation were 
that short-term dietary nitrate supplementation did not reduce the O2 cost of walking, or increase 
the distance covered in the six minute walk test in this population. We also confirmed our 
previous finding that nitrate supplementation had no effect on resting blood pressure in 
individuals with T2DM. These findings may be considered surprising given the compelling 
effects of dietary nitrate supplementation reported in other populations. Possible explanations for 
the lack of effects in the present study relate to an elevated baseline plasma nitrite concentration 
in the control condition, and/or reductions in the bioavailability of NO in individuals with 
T2DM. 
Nitrate supplementation and plasma nitrate and plasma nitrite concentration.  
Plasma nitrate and nitrite concentrations were significantly elevated following nitrate 
supplementation, which is consistent with previous studies examining young 15,16 and older  
healthy participants 39, and individuals with peripheral arterial disease 40. The post placebo 
plasma nitrite concentration was approximately two to six-times higher in the present study than 
those reported in the aforementioned studies. The elevated plasma nitrite concentration in 
individuals with T2DM in the placebo condition may be associated with the habitual up-
regulation of iNOS which is endemic in this population 41. It is possible that the elevated baseline 
(placebo) plasma nitrite concentration is indicative of disease pathology and mitigates the 
attainment of the benefits of dietary nitrate supplementation that have been reported in other 
populations. 
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The plasma nitrite concentration was 680 ± 256 nM in the placebo arm in the present 
study.  In the only other study which could be directly comparable, the  plasma nitrite 
concentration was 232 nmol/L (200, 265), median (IQR) in the placebo arm 34. The control 
plasma from Gilchrist, Winyard, Aizawa, Anning, Shore, Benjamin 34 was re-measured during 
the current study to establish agreement between the nitrite values measured in the two studies.  
It is therefore unlikely that analytical error is the reason for our elevated ‘baseline’ plasma nitrite 
concentrations. There are notable differences between the two studies with respect to the timing 
of beetroot juice doses and plasma sampling.  In the present work, studies were conducted at 
midday, with subjects having had breakfast including the beetroot juice and their usual morning 
hypoglycaemic and antihypertensive medications 3 hours previously. In our previous study in 
subjects with T2DM 30, plasma sampling occurred after an overnight fast, with subjects having 
omitted their usual morning hypoglycaemic and antihypertensive medications, 16 hours after 
their last beetroot juice.   
Multiple agents within these broad classes of medication have been shown to up-regulate 
eNOS activity 42-44. When the current cohort was split for drug classifications, no differences in 
baseline plasma nitrite were detectable. It is therefore unlikely that drug classification affected 
plasma nitrite concentrations, though the study was not powered to detect any such difference.  
Furthermore, there are data to suggest circadian variation in eNOS activity, with the lowest 
levels in the morning, rising through the day before falling again at night 45. This could further 
influence the difference between plasma nitrite concentrations in the two groups. With a growing 
number of studies in patient groups, understanding the effect of concomitant medication on 
plasma nitrite and nitrate concentrations is becoming increasingly important. Accordingly, 
sufficiently powered research is required to examine the pharmacokinetics and dynamics of 
21 
 
medications and NOx concentrations in order to elucidate the possibility of nitrate related 
therapeutic effects on exercise performance. 
 
Nitrate supplementation and pulmonary oxygen uptake  
There was no difference between active and placebo juice in the V̇O2 responses to low 
intensity walking exercise in the present study. A reduction in the baseline 31 and steady state 
15,31,46 O2 cost of low intensity exercise has previously been reported in young healthy individuals 
following similar nitrate dosage regimens to that which was implemented in the present study. 
No change in the O2 cost of exercise was reported in healthy older individuals following nitrate 
supplementation 39. However, these authors reported a significant speeding of the V̇O2 kinetics, 
something that was not observed in the present study.  It is therefore unlikely that aging per se 
explains the lack of effect on the V̇O2 kinetics in the present study. Other studies have reported 
no significant difference in the V̇O2 response to exercise subsequent to nitrate supplementation in 
healthy, well-trained athletes 47,48. This lack of effect has also been reported in individuals with 
COPD 30,49,50. These studies all had relatively small sample sizes (n = 847, 1148,51, 1349, and 1530). 
One possible explanation for the lack of effect on the oxygen cost of exercise may relate 
to the elevated plasma nitrite concentration in the placebo condition (baseline) of this study 
which might reduce the scope for the further increases in plasma nitrite concentration that have 
been realised via nitrate supplementation in other populations. Thus the lack of effect of dietary 
nitrate supplementation on the O2 cost of exercise noted in the present study may indicate the 
existence of an upper limit for the baseline plasma nitrite concentration, beyond which the scope 
for positive effects from further increasing plasma nitrite concentration is reduced.  In support of 
this suggestion, a significant negative correlation has been reported between the changes in 
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plasma nitrite concentration with beetroot juice vs. placebo juice and the change in performance 
during cycling exercise (i.e. participants whose plasma nitrite increased more following nitrate 
supplementation experienced a greater improvement in exercise performance, and vice versa) 47. 
However, in the current study there was no correlation between either placebo plasma nitrite 
concentration, or change in plasma nitrite concentration with nitrate rich vs. placebo juice, and 
the O2 cost of exercise.   
An alternative suggestion for the lack of effect of nitrate supplementation on the O2 cost 
of exercise may be related to the reduction in the bioavailability of NO which has been reported 
in individuals with T2DM 52-54. This reduced bioavailability has been linked with the 
concentration of plasma ADMA (an analogue of L-arginine), which is elevated in individuals 
with T2DM 55. ADMA is known to inhibit all three NOS isoforms, particularly eNOS 56, leading 
to eNOS uncoupling and the generation of superoxide radicals 57, ultimately resulting in 
increased oxidative stress. When NO and superoxide react, peroxynitrite is generated. This is 
known to result in a quenching of NO activity and thus a reduction in its bioavailability, which 
may serve to diminish any positive impact of nitrate supplementation 58,59. Furthermore, 
sustained exposure to oxidative and nitrative stress could result in damage to mitochondrial 
membranes 60 and thus reduce the P/O ratio (i.e more O2 would be required to produce a given 
amount of ATP). It is possible that damaged mitochondria associated with T2DM 60 means that 
this population are less likely to benefit from the improved mitochondrial function subsequent to 
nitrate supplementation, which may underpin, in part, the reduced O2 cost of exercise in healthy 
individuals 10.  
A further possible explanation for the lack of effect of nitrate supplementation on the 
exercise response in individuals with T2DM may relate to pathological consumption of nitrite 
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during exercise. Post-exercise plasma nitrite concentration has been shown to fall markedly in 
individuals with cardiovascular risk factors 61 compared with the response reported in healthy 
individuals 62. This may suggest that either the production of NO cannot keep up with metabolic 
demand, or the NO produced is scavenged more rapidly in individuals with cardiovascular risk 
factors compared with healthy individuals.  It is plausible that a similar effect is seen in 
individuals with T2DM, with a marked net consumption of plasma nitrite during exercise. It 
should be noted, however, that this would not explain the lack of effect of nitrate 
supplementation on BP in our study as these measurements were conducted at rest. 
It should be noted that although we have postulated a pro-oxidant state as an explanation 
for the lack of effect of nitrate supplementation in individuals with T2DM, beneficial effects of 
nitrate have been seen in other patient groups who are likely to be in a pro-oxidant state. Zamani 
et al., 63 reported an improvement in exercise capacity (but no reduction in the oxygen cost of 
exercise) following beetroot juice supplementation in individuals with heart failure. Similar 
findings have been reported in individuals with peripheral artery disease 40 and chronic 
obstructive pulmonary disease 30,49,51. It should be noted, however, that to date no study has 
shown a reduction in the oxygen cost of exercise in a patient group, despite reporting 
improvements in exercise tolerance. It is feasible that the improvement in exercise tolerance in 
the aforementioned studies is associated with elevated muscle blood flow consequent to an 
elevated plasma nitrite concentration 64, although this requires further investigation to confirm. 
Nitrate supplementation and functional Capacity. 
There was no difference between the active and placebo juice conditions for the distance 
covered in the 6MWT.  This is consistent with the only other study to have investigated the 
impact of nitrate supplementation on exercise performance using the 6MWT (in healthy older 
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individuals) 39. Since any improvement in walking performance could reasonably be assumed to 
be underpinned by alterations in the V̇O2 response to exercise, and considering that this was not 
modulated by nitrate supplementation, it is perhaps not surprising that functional capacity was 
also not different between conditions. It is likely that the explanation for the lack of effect of 
nitrate supplementation on walking performance is synonymous with the potential explanations 
for the lack of effect on the O2 cost of exercise (see previous section).  
Walking performance has been shown to be enhanced in individuals who are taking 
ACEi 65. Our cohort included 48% of individuals on ACEi and/or ARBs, thus any potential 
improvements in walking performance subsequent to nitrate supplementation may have been 
masked. When we separated the group into those prescribed ACEi or ARBs compared to the 
remaining individuals, no difference was seen between groups for walking performance. The 
groups were split 48% (n = 23) with prescribed ACEi or ARBs and 52% (n = 25) not taking 
ACEi/ARB.  One possible explanation for the finding is that the 6MWT was the last of the 
experimental procedures to be conducted and followed 18 minutes of treadmill walking. The 
prior exercise (and time since last nitrate supplementation) may have meant that some of the 
additional nitrite which was available following nitrate supplementation had been utilised, 
especially given our cohort’s elevated cardiovascular risk 61. 
Nitrate supplementation and resting blood pressure. 
 In agreement with our previous study examining the effect of dietary nitrate 
supplementation on blood pressure in individuals with T2DM 34, we found no difference in BP 
between conditions.  Nitrate doses similar to that which was administered in the present study 
(6.43 mmol per day) have elicited reductions in diastolic BP in healthy young individuals 15 and 
25 
 
those with peripheral arterial disease 40, and reduced  systolic BP in healthy young 15,17,31 and old 
39 individuals.  
There are a number of possible explanations for the lack of effect of nitrate 
supplementation on the resting BP of individuals with T2DM.  A reduced NO responsiveness has 
been linked to vascular stiffening in older individuals 66. However, aging per se is unlikely to 
explain the lack of effect in the present study as BP was significantly reduced subsequent to 
nitrate supplementation in healthy older adults (on no medication) 39. Secondly, the elevated 
oxidative stress prevalent in individuals with T2DM would be expected to result in an increase in 
the scavenging of NO, potentially diminishing any hypotensive effects from nitrate 
supplementation. 
Antioxidants in beetroot juice  
It has been demonstrated that the beneficial effects of beetroot juice are largely explained 
by its nitrate content 31.  However, it has also been suggested that an antioxidant effect may also 
be occurring, such as is observed under in vitro experiments with polyphenols 67. Though there 
are small differences in antioxidants between the two juices used (placebo and active), the 
magnitude of this difference is unlikely to be physiologically relevant.  Typical total daily 
polyphenol intake across multiple populations has been estimated to be in the region of 1g daily 
68;   the effective dose from either juice in the current study therefore represents less than 1% of 
average total intake. Betacyanins were present in much higher quantities.  The bioavailability of 
these compounds is however uncertain, but it appears to be very low with typical estimates from 
<1% to 4% of an oral dose, with some individuals having far greater absorption 69,70. 
Furthermore, the removal of betanin from plasma is rapid, with a t1/2 of 0.94±0.07 hours. These 
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factors suggest the betacyanin content of beetroot juice is unlikely to have a clinically 
meaningful effect.  
 
Strengths and limitations.  
To date this is the largest trial, implementing robust methods, to examine the effect of 
inorganic nitrate or pharmacological nitrate supplementation on the O2 cost of exercise.  The a 
priori sample size calculation was designed to enable the study to detect an 8% reduction in the 
O2 cost of low intensity exercise with a 0.05 alpha level and an 80% power. From the 95% CI it 
is likely that the actual difference for the O2 cost of low intensity exercise following nitrate 
supplementation in individuals with T2DM was between -2.1% and 3.6%. Therefore the 
minimum detectable reduction in the O2 cost of exercise in our study is 2.1%. This is very 
similar to the day to day variability of V̇O2 measurement, thus it is unlikely that a larger sample 
size would elucidate a clinically significant difference in the O2 cost of walking exercise in this 
patient group. A potential limitation of the present study is that the 6MWT was completed up to 
4 hours subsequent to the consumption of the final beverage, and after 18 minutes of  walking 
when the increments in nitrite from supplementation may have been utilised already.   As plasma 
nitrite concentration was not determined prior to the 6MWT, we cannot be certain that this 
remained elevated following nitrate supplementation compared to the placebo condition.  
However, this does mean that the study provides knowledge of the level of improvement (or lack 
of it) that a patient with type 2 diabetes could expect in the early afternoon of normal daily 
living. 
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Conclusion         
In contrast to much of the literature in young healthy individuals and despite a 
statistically significant and physiologically meaningful increase in plasma nitrite concentration, 
four days of beetroot juice supplementation with 6.43 mmol of nitrate did not reduce the O2 cost 
of walking, improve functional capacity as determined by the 6MWT, or reduce resting BP in 
individuals with T2DM. The lack of effects of dietary nitrate supplementation in individuals with 
T2DM may be explained by increased oxidative stress and its impact on the bioavailability of 
NO, or an elevated ‘baseline’ plasma nitrite concentration which reduces the scope for the 
beneficial effects reported in other populations.  
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